Anthera Pharmaceuticals 

We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Find out more about what we are doing for patients with Cystic Fibrosis and IgA Nephropathy:

Cystic Fibrosis
IgA Nephropathy
LATEST NEWS

Anthera Announces Completion of Dosing in the Phase 2 BRIGHT-SC Study of Blisibimod in Patients with IgA Nethropathy. Read more

Anthera Pharmaceuticals Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants. Read more

Print Friendly